Literature DB >> 10912742

The use of antihypertensive therapy in Spain (1986-1994).

N S Jabary1, A M Herrero, J A Gonzalez.   

Abstract

We aimed to analyze the trends in antihypertensive therapy in Spain during the period 1986 to 1994, as well as the change in the pattern of different drugs, in relation to different national/international recommendations for hypertension treatment. Antihypertensive consumption was studied using the defined daily dose (DDD) and the DHD (DDD/1000 inhabitants/day) of each drug, as defined by the Drug Utilization Research Group of the European Office of the World Health Organization. The anatomical classification of hypotensive drugs has been made according to EPhMRA (European Pharmaceutical Market Association) guidelines. A significant increase of 117.4% (41.39/90 DHD) in antihypertensive drug consumption was observed in the period 1986 to 1994. In 1986 diuretics were the most consumed (30.27 DHD), followed by calcium antagonists (5.37), beta-blockers (3.93), and the angiotensin-converting enzyme (ACE) inhibitor (1.37). In 1994 ACE inhibitors, calcium antagonists, and beta-blockers increased significantly (P < .0001), whereas diuretics were still the most commonly prescribed. Nifedipine and captopril were the most used among calcium antagonists and ACE inhibitors. National and international recommendations had no effect on prescription patterns. Antihypertensive therapy of all types is increasing in Spain. Diuretics remain the most popular, beta-blockers stay stable, whereas the newer types are rising rapidly. National and international recommendations had no effect on prescription patterns.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10912742     DOI: 10.1016/s0895-7061(99)00261-7

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  3 in total

Review 1.  [Use of prescription drugs in Spain and Europe].

Authors:  Juan Simó Miñana
Journal:  Aten Primaria       Date:  2011-10-22       Impact factor: 1.137

2.  Role of arachidonoylethanolamine in blood pressure regulation in volume-resistant patients on peritoneal dialysis.

Authors:  Qiong Bai; Jing Zhang; Ai-Hua Zhang; Li-Tao Cheng; Jing-Li Duan; Lian He; Ya-Jun Luo; Min-Hua Fan; Yue Wang; Tao Wang
Journal:  Int Urol Nephrol       Date:  2012-03-24       Impact factor: 2.370

3.  Metabolic syndrome and its components associated with endothelial dysfunction in chronic kidney disease patients.

Authors:  Qiong Bai; Xuan Lai; Ai-Hua Zhang; Xin-Hong Lu; Shun-Li Tian; Min-Hua Fan; Yue Wang; Tao Wang
Journal:  Vasc Health Risk Manag       Date:  2012-01-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.